BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Hemobiotech, Inc. Signs Third Stage Sponsored Research Agreement With Texas Tech University Health Sciences Center


1/18/2006 10:56:47 AM

DALLAS, Jan. 18 /PRNewswire/ -- HemoBioTech, Inc. announced today that it has signed a third stage Sponsored Research Agreement (SRA) with Texas Tech University Health Sciences Center (TTUHSC). The SRA will focus on the manufacture of clinical grade HemoTech(TM).

The third stage SRA follows a second stage SRA between HemoBioTech and TTUHSC which was completed in December of 2005. The second stage SRA included: 1) Upgrade of the HemoTech(TM) production facility; 2) Digitization and analysis of CMC (Chemistry, Manufacturing and Controls) pre-clinical and clinical data; 3) Creation of a bovine blood donor facility; 4) Preparation of new HemoTech(TM) patents; 5) Preparation of a US IND (Investigation of a New Drug) needed for US clinical studies.

"We are very pleased with the program at Texas Tech. We are now focusing on the manufacture of HemoTech(TM) which is needed for further expansion of the HemoTech(TM) program," said Dr. Arthur P. Bollon, Chairman and Chief Executive Officer of HemoBioTech.

About HemoBioTech, Inc.

HemoBioTech is engaged in the development of HemoTech(TM), a novel human blood substitute technology exclusively licensed from Texas Tech University Health Sciences Center. HemoTech(TM) is a chemically modified hemoglobin which not only carries oxygen in the blood, but can also induce red blood cell production. The Company believes that HemoTech(TM) may possess properties that diminish the intrinsic toxicities which have plagued other attempts at developing blood substitutes, based upon pre-clinical and initial human clinical trials undertaken outside the U.S. by prior holders of this technology. HemoTech(TM) is being developed to help reduce or eliminate the danger resulting from acute blood loss in trauma, as well as for other applications. Corporate headquarters are located at J. P. Morgan International Plaza, 14221 Dallas Parkway, Suite 1500, Dallas, Texas 75254, and the Company telephone number is 214-540-8411. The Company website is www.hemobiotech.com.

Contact: Dr. Arthur Bollon of HemoBioTech, Inc., +1-214-540-8411

HemoBioTech, Inc.

CONTACT: Dr. Arthur Bollon of HemoBioTech, Inc., +1-214-540-8411



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->